Introduction

53
Listeria monocytogenes is a common environmental Gram positive bacterium 54 that upon ingestion can cause the serious disease listeriosis (1). Listeriosis is normally 55 contracted from ingestion of contaminated food by at risk populations which include the 56 elderly, the immunocompromised and pregnant women (2-3). Disease symptoms can 57 range from mild gastroenteritis to severe meningitis and spontaneous miscarriage (4).
58
Current therapy calls for high dose aminopenicillins combined with gentamicin (5).
59
Although L. monocytogenes is highly susceptible to this treatment in vitro, the fatality 60 rate from confirmed cases of listeriosis remains high, sometimes reaching ~30%,
61
suggesting an increased need for better therapeutic strategies (6-7). 
89
Here, we test the hypothesis that pharmacologic inhibition of the PASTA kinase 
93
We demonstrate that L. monocytogenes is resistant to treatment with the non-specific 94 kinase inhibitor staurosporine, but that combination therapy with β-lactam antibiotics and 95 staurosporine leads to an ~100 fold increase in susceptibility to the β-lactam antibiotic.
96
Importantly, the synergistic effect was only observed with β-lactams and not with other 
125
(Sigma-Aldrich) was used at a final concentration of 2 µg/ml, chloramphenicol (Sigma-
126
Aldrich) was used at 10μg/ml and kanamycin (Sigma-Aldrich) was used at 20 µg/ml. 
137
All growth experiments were repeated at least three times. For all in vitro growth 138 assays, staurosporine (Calbiochem, Billerica, MA) was used at a final concentration of 139 10 µM, AZD5438 (Selleck Chemicals, Houston) was used at 50μM, and antibiotics were 140 used at the concentrations specified in the figure legends.
141
For minimal media experiments, cultures were grown brain heart infusion (BHI) 
147
kinase domains were amplified (JDS50 -SA-STPK-R- Table 1 ) and ligated into the 148 expression vector GEX-2T to construct a glutathione S transferase (GST) fusion protein.
149
The plasmids were transformed into Rosetta E. coli BL21, and protein expression was 
158
The bound protein was eluted using disposable chromatography columns (Thermo
159
Scientific, Rockford, IL) and an elution buffer containing 50 mM Tris (pH 8.0) and 20 mM 160 reduced glutathione. The fractions were assessed for purity via SDS-PAGE, and
161
fractions with estimated >95% purity were concentrated via centrifugation and
162
glutathione was removed and exchanged with 1X PBS using a buffer exchange unit
163
(Amicon, Billerica, MA).
164
In vitro protein phosphorylation. 
204
Deletion of the PASTA kinase in L. monocytogenes (Fig. 1) 
209
Staurosporine treatment alone had a minimal effect on L. monocytogenes growth (Fig. 2 
210
A-E, Fig. S1 ). Similarly, sub-inhibitory concentrations of antibiotic had no effect on L.
211
monocytogenes growth ( Fig. 2A-E) . However, treatment of L. monocytogenes with sub- 
217
or ribosome inhibitors such as kanamycin, was unaffected (Fig. 2 D, E) . Additionally, 
236
Basic Protein (MBP) (Fig. 3) . However, only PrkA, and not Lmo0618, was inhibited by (Fig. 4A red lines) , however, whereas wild type L. monocytogenes 254 become at least 10-fold more susceptible to ceftriaxone in the presence of 5μM 255 staurosporine, the sensitivity of ΔprkA mutants does not change appreciably in the 256 presence of staurosporine (Fig. 4B red lines) . These data, taken together with the biochemical inhibition data further suggest that staurosporine sensitizes wild type L. 
272
Similar to staurosporine, we observed that AZD5438 specifically inhibits PrkA while not 273 inhibiting Lmo0618 (Fig. 5B) . A higher resolution dose response curve shows 274 autophosphorylation and substrate phosphorylation both being inhibited in a dose 275 dependent manner in parallel (Fig.. 5C) . Taken together this data suggests that both 
313
( Fig. 2F) or directly inhibit Stk1 (Fig. 3) , suggesting that selectivity of bacterial kinase 314 inhibition is possible. Furthermore, we observed additional evidence of kinase specific 315 selectivity with a different inhibitor, AZD5438. While AZD5438 is not as potent an 316 inhibitor of PrkA as it is of the human kinases that it was optimized to inhibit (CDK-2)
317
(29), AZD5438 does inhibit PrkA at concentrations for which no effect is seen on
318
Lmo0618. The specific residues that confer inhibitor specificity towards bacterial eSTKs 319 remain to be defined. These differences are likely in the ATP binding pocket of the 
